Show the full website


NMD Pharma treats first patient with the firm's most promising drug candidate

Biotech NMD Pharma, which received a DKK 280m investment 2.5 years ago, has treated the first patient in a clinical trial investigating the company's most promising medical drug candidate.

NMD Pharma CEO Thomas Holm Pedersen | Foto: PR / NMD Pharma

The first patient has now received treatment with the drug candidate NMD 679 from NMD Pharma, which is testing the use of the drug for the neuromuscular disease myasthenia gravis (MG).

The company, which was formed in 2015, states this in a press announcement.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Receive newsletter from MedWatch today

NB: Subscribing to the newsletter is free.

More from MedWatch


See all jobs